GYRE
GYRE THERAPEUTICS, INC.Company Information
- Company Name
- GYRE THERAPEUTICS, INC.
- CIK
- CIK0001124105
- Category
- Accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- GYRE: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- GYRE
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-06-11
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 72,377
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 8,830,884
- Shares outstanding
- 100,637,599
- Ownership
- 8.77%
Earnings Market Reaction
- Filing date
- 2026-08-07
- Price on filing date
- —
- 1-month reaction
- -1.20%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Preferred Stock | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Related Party | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 1 | 1 | 0 | ||||||
| G C Biopharma Corp | - | - | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 5 | 5 | 0 | ||||||
| Cullgen | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
Assets Current | ||||||||||||||||||
| Redeemable Preferred Stock | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Cash And Cash Equivalents At Carrying Value | 43 | 38 | 37 | 40 | 36 | 15 | 12 | 16 | 16 | 30 | 34 | 2 | ||||||
| Prepaid Insurance | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Short Term Investments | 14 | 12 | 15 | 20 | 18 | 15 | 15 | 9 | 9 | 8 | - | - | ||||||
| Accounts Notes And Loans Receivable Net Current | - | - | - | - | - | - | - | 19 | 19 | 15 | 16 | - | ||||||
| Available For Sale Securities Debt Securities | 17 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Notes And Loans Receivable Net Current | 0 | 4 | 6 | 1 | 0 | 2 | 4 | - | - | - | 0 | - | ||||||
| Accounts Receivable Net Current | 28 | 23 | 31 | 26 | 25 | 20 | 20 | - | - | - | 15 | - | ||||||
| Inventory Gross | - | 11 | 10 | 9 | - | - | 6 | - | - | - | - | - | ||||||
| Other Assets Current | - | - | 1 | - | - | - | 1 | 2 | 2 | 2 | 1 | - | ||||||
| Inventory Net | 11 | - | - | - | 9 | 8 | 6 | 6 | 6 | 5 | 4 | - | ||||||
| Prepaid Expense And Other Assets Current | 8 | 4 | - | 3 | 3 | 8 | - | - | - | - | - | - | ||||||
| Assets Current | 122 | 92 | 102 | 99 | 91 | 68 | 65 | 55 | 54 | 63 | 57 | 5 | ||||||
| Property Plant And Equipment Net | 27 | 24 | 24 | 24 | 23 | 24 | 24 | 24 | 24 | 24 | 23 | - | ||||||
| Finite Lived Intangible Assets Net | 5 | 5 | 5 | 5 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Operating Lease Right Of Use Asset | - | - | 1 | - | - | - | 2 | 2 | 2 | 0 | 0 | - | ||||||
| Prepaid Expense Noncurrent | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Deferred Income Tax Assets Net | 9 | 8 | 7 | 7 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | - | ||||||
| Other Assets Noncurrent | 7 | 5 | 2 | 5 | 5 | 6 | 3 | 3 | 1 | 1 | 1 | 0 | ||||||
| Assets | 199 | 162 | 166 | 159 | 153 | 130 | 125 | 125 | 121 | 122 | 117 | 10 | ||||||
Liabilities Current | ||||||||||||||||||
| Other Accrued Liabilities Current | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Accounts Payable Current | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accrued Employee Benefits Current | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Deferred Revenue Current | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | - | ||||||
| Contract With Customer Liability Current | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Other Liabilities Current | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | - | ||||||
| Accrued Liabilities And Other Liabilities | 19 | 15 | 14 | 12 | 15 | 17 | 11 | 10 | 11 | 11 | 12 | - | ||||||
| Accrued Income Taxes Current | 2 | 3 | 3 | 3 | 1 | 1 | 3 | 3 | 2 | 6 | 5 | - | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | - | ||||||
| Liabilities Current | 29 | 20 | 18 | 16 | 17 | 19 | 20 | 15 | 16 | 19 | 20 | 2 | ||||||
| Operating Lease Liability Noncurrent | 2 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | - | ||||||
| Deferred Revenue Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | - | ||||||
| Derivative Liabilities Noncurrent | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 6 | 6 | 9 | 13 | - | ||||||
| Other Liabilities Noncurrent | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Liabilities | 34 | 25 | 24 | 22 | 23 | 25 | 27 | 27 | 28 | 33 | 38 | 6 | ||||||
| Preferred Stock Value | - | - | - | - | - | - | - | - | - | - | - | 33 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | - | - | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | - | - | - | - | - | - | - | 5 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 241 | 175 | 172 | 167 | 161 | 138 | 136 | 134 | 134 | 133 | 68 | 385 | ||||||
| Retained Earnings Accumulated Deficit | -138 | -78 | -68 | -67 | -70 | -71 | -73 | -73 | -74 | -78 | -86 | -415 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 1 | 1 | -1 | -2 | -2 | -2 | -3 | -1 | -2 | -2 | -2 | - | ||||||
| Stockholders Equity | 108 | 137 | 142 | 102 | 92 | 68 | 63 | 98 | 93 | 57 | 14 | 4 | ||||||
| Minority Interest | 35 | 36 | 36 | 35 | 37 | 36 | 35 | 35 | 33 | 32 | 30 | - | ||||||
| Liabilities And Stockholders Equity | 199 | 162 | 166 | 159 | 153 | 130 | 125 | 125 | 121 | 122 | 117 | 10 | ||||||
| Convertible Preferred Stock | - | 0 | 0 | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Redeemable Convertible Preferred Stock | 0 | - | - | - | 3 | - | - | - | - | - | - | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 100 | ||||||
| Common Stock Shares Issued | 106 | 91 | 91 | 91 | 91 | 88 | 86 | 86 | 86 | 85 | 77 | 38 | ||||||
| Shares Outstanding | 106 | 91 | 91 | 91 | 91 | 88 | 86 | 86 | 86 | 85 | 77 | 38 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialGYRE THERAPEUTICS, INC. (GYRE) — SEC Financial Statements & Analysis
GYRE THERAPEUTICS, INC. (GYRE) is a pharmaceutical preparations company, incorporated in DE. GYRE THERAPEUTICS, INC. trades on Nasdaq as: GYRE. GYRE THERAPEUTICS, INC. (GYRE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07. Based on that filing, GYRE THERAPEUTICS, INC. carries a market cap of $663.20M, a P/E ratio of -41.50x, a P/B ratio of 6.14x, a P/S ratio of 5.70x, an enterprise value of $619.91M, and an EV/EBITDA multiple of -67.59x. On profitability, it posts a gross margin of 94.15%, an operating margin of -10.53%, a net margin of -13.73%, a Return on Equity (ROE) of -15.98%, a Return on Assets (ROA) of -9.08%, and a Return on Invested Capital (ROIC) of -19.68%. Per share, it reports EPS of $-0.16, diluted EPS of $-0.16, free cash flow per share of $-0.06, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 10.72% year-over-year, net income growth of -1051.82% year-over-year, and EPS growth of -942.88% year-over-year. On the balance sheet, it maintains a current ratio of 4.26x, a quick ratio of 3.59x, working capital of $93.41M, a debt-to-equity ratio of 0.32x, a debt ratio of 0.17, an interest coverage ratio of -16.57x, free cash flow of $-6.11M (TTM), and net debt of $-43.29M. Figures sourced from SEC EDGAR.
- Market Cap
- $663.20M
- P/E TTM
- -41.50x
- EPS TTM
- $-0.16
- P/B TTM
- 6.14x
- ROE TTM
- -15.98%
- ROA TTM
- -9.08%
- Debt To Equity
- 0.32x
- Free Cash Flow TTM
- $-6.11M
- Net Revenue TTM Growth 1Y
- 10.72%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is GYRE THERAPEUTICS, INC. in?
GYRE THERAPEUTICS, INC. (GYRE) operates in the Pharmaceutical Preparations industry.
What exchange does GYRE trade on?
GYRE THERAPEUTICS, INC. (GYRE) trades on the Nasdaq.
Where is GYRE THERAPEUTICS, INC. incorporated?
GYRE THERAPEUTICS, INC. is incorporated in DE.
When was GYRE THERAPEUTICS, INC. (GYRE)'s most recent SEC filing?
GYRE THERAPEUTICS, INC. (GYRE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07.
What is GYRE's market cap?
GYRE THERAPEUTICS, INC. (GYRE) has a market capitalization of $663.20M as of 2026-06-30.
What is GYRE's EPS (earnings per share)?
GYRE THERAPEUTICS, INC. (GYRE)'s trailing twelve month EPS is $-0.16 as of 2026-06-30.
What is GYRE's ROE (return on equity)?
GYRE THERAPEUTICS, INC. (GYRE)'s trailing twelve month Return on Equity (ROE) is -15.98% as of 2026-06-30.
What is GYRE's ROA (return on assets)?
GYRE THERAPEUTICS, INC. (GYRE)'s trailing twelve month Return on Assets (ROA) is -9.08% as of 2026-06-30.
What is GYRE's ROIC (return on invested capital)?
GYRE THERAPEUTICS, INC. (GYRE)'s trailing twelve month Return on Invested Capital (ROIC) is -19.68% as of 2026-06-30.
What is GYRE's EV/EBITDA?
GYRE THERAPEUTICS, INC. (GYRE)'s trailing twelve month EV/EBITDA is -67.59x as of 2026-06-30.